Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine
Nov 12, 2014
Sandoz launches new ready to use oral formulation of ACC® in the Ukrainian market
ACC® oral solution is used for children from 2 years old
New form has cherry flavor and is available with convenient dispenser
Kiev, November 12, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.
ACC® oral solution (active substance acetylcysteine) is used to treat acute and chronic bronchopulmonary diseases when it is necessary to reduce the viscosity of mucus, improving its discharge and coughing.
The medicine is indicated for the treatment of adults and children from 2 years old. A measuring cap and / or applicator (syringe) ensure convenient and accurate dosage when taking the medicine.
“We are pleased to launch this new ready-to-use oral formulation of ACC® in Ukraine, which is used as cough medicine to treat bronchopulmonary diseases. ACC® is a market leader in its category of medicines1 and won the Favorites of Success 2013 prize in the cough medicine category,” said Robert Trnovsek, Country Head of Sandoz Ukraine. “The launch of ACC® is part of Sandoz Ukraine’s strategy to offer a broad portfolio of high quality medicines to patients in Ukraine.”
The new ready-to-use oral formulation is available in a solution with a cherry flavor (the medicine contains cherry flavorings), especially appealing to children, but without added sugar.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).